SENTIEN BIOTECHNOLOGIES, INC.

Address

196 Boston Ave
MEDFORD, MA, 02155-4236

Information

DUNS: 828970900
# of Employees: 4

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Stem Cell Bioreactor for Cardiac Care

    Amount: $1,012,556.00

    DESCRIPTION provided by applicant The goal of this Fast Track Phase I II SBIR is to test a novel extracorporeal system for delivering mesenchymal stem cell MSC secretions to treat acute myocardia ...

    SBIRPhase I2016Department of Health and Human Services
  2. Stem Cell Bioreactor for Cardiac Care

    Amount: $771,827.00

    DESCRIPTION provided by applicant The goal of this Fast Track Phase I II SBIR is to test a novel extracorporeal system for delivering mesenchymal stem cell MSC secretions to treat acute myocardia ...

    SBIRPhase II2016Department of Health and Human Services
  3. Transforming Dialysis into a Controlled Drug Delivery System for Stem Cell Derive

    Amount: $2,985,949.00

    DESCRIPTION (provided by applicant): The goal of this Phase IIB SBIR application is to test the Sentien cellular bioreactor product (the Sentinel ) in a first-in-man study to assess safety and prelimi ...

    SBIRPhase II2014Department of Health and Human Services
  4. Transforming Dialysis into a Controlled Drug Delivery System for Stem Cell Derive

    Amount: $2,985,949.00

    DESCRIPTION provided by applicant The goal of this Phase IIB SBIR application is to test the Sentien cellular bioreactor product the Sentinelandquot in a first in man study to assess safety and ...

    SBIRPhase II2014Department of Health and Human Services
  5. Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failure

    Amount: $773,285.00

    DESCRIPTION (provided by applicant): The overall goal of this project is to design a clinical protocol for the operation and monitoring of a mesenchymal stem cell (MSC)-coated dialysis device for the ...

    SBIRPhase II2012Department of Health and Human Services
  6. Blood Purification for Organ Failure

    Amount: $99,974.00

    Sentien Biotechnologies is developing cellular devices for the treatment of acute organ failure, including polytrauma-induced multiple organ dysfunction syndrome (MODS). Our flagship product, the Sent ...

    SBIRPhase I2012Department of Defense
  7. Cellular Device for the Treatment of Acute Liver Failure

    Amount: $499,306.00

    DESCRIPTION (provided by applicant): The goal of this Phase I project is to develop a cell-coated device for the treatment of acute liver failure. The device harnesses mesenchymal stem cell secretions ...

    SBIRPhase I2012Department of Health and Human Services
  8. A Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failur

    Amount: $565,011.00

    DESCRIPTION (provided by applicant): The overall goal of this Phase I project is to create technical protocols for the reproducible operation of our proprietary cell-based device for the treatment of ...

    SBIRPhase I2010Department of Health and Human Services
  9. SBIR Phase I:Assembly and Storage of Cell-Derived Drug Delivery Devices

    Amount: $150,000.00

    This Small Business Innovation Research (SBIR) Phase I project proposes the development of a stem cell-based extracorporeal device that can offer unparalleled support to 200,000+ patients undergoing s ...

    SBIRPhase I2010National Science Foundation

Agency Micro-sites

US Flag An Official Website of the United States Government